Gloria Spectrum

About Gloria Spectrum

Calibra Scientific, Inc., also known as Gloria Spectrum in China, operates as an integrated platform for mass spectrometry applications, focusing on precision medicine. The company was founded in 2017 by Hua-fen Liu, who now serves as the Chief Executive Officer. Liu's background includes key roles in the clinical mass spectrometry industry in both the US and China, with previous positions at SCIEX, Roche, and Pfizer, providing a deep foundation in the sector that directly informs Calibra's direction.

The company's business model is centered on a multi-omics, data-driven strategy to develop products for precision diagnosis and treatment. It generates revenue through several channels: the sale of in-vitro diagnostic (IVD) registered clinical mass spectrometry detection systems and reagent kits, providing central laboratory testing services, and engaging in multi-omics research and development. Calibra serves a broad market of over 20,000 hospitals and research institutions, primarily located in China.

Calibra's core offerings include the CalOmics multi-omics R&D and productization platform and the CalQuant-S clinical mass spectrometry detection system. The company has developed more than 10 NMPA class II clinical mass spectrometry reagent kits and offers over 300 clinical testing assays. These services cover areas like health management, nutritional analysis, and endocrine system assessment. The technology combines liquid chromatography for high separation with tandem mass spectrometry for specificity, enabling accurate quantitative analysis of complex biological samples for applications such as newborn metabolic disease screening and therapeutic drug monitoring.

Since its establishment, the company has actively built its intellectual property portfolio, applying for over 100 patents and copyrights. It has also contributed to the scientific community by publishing numerous academic articles in journals. The company's funding history includes a Series A round in November 2020 and subsequent venture rounds to support its growth.